Amgen Says A Second Phase 3 Clinical Trial Is Ongoing In Japan Evaluating TEPEZZA Among Adults With Chronic TED And A Low CAS
Amgen Says A Second Phase 3 Clinical Trial Is Ongoing In Japan Evaluating TEPEZZA Among Adults With Chronic TED And A Low CAS
安进表示，在日本正在进行第二阶段3临床试验，评估TEPEZZA对慢性TED和低CAS的成年人的疗效。
The primary endpoint in the trial was met, as 89% of patients treated with TEPEZZA had a clinically meaningful improvement in proptosis (≥2 mm) compared with placebo (11%; p<0.0001) at week 24. The safety profile was consistent with the complete body of clinical data supporting TEPEZZA.3 A second Phase 3 clinical trial is ongoing in Japan evaluating TEPEZZA among adults with chronic TED and a low CAS (jRCT2031220730).
试验的主要终点已达成，89%接受TEPEZZA治疗的患者在24周时，眼球前突得到临床意义重大的改善（≥2mm），明显优于安慰剂组（11%；p
资讯热榜
更新时间